Core G: Biomarker Core

核心 G：生物标志物核心

• 批准号: 10378033
• 负责人: Craig E Stark
• 金额: $ 32.42万
• 依托单位: UNIVERSITY OF CALIFORNIA-IRVINE
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-15 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10378033
• 关键词: Abbreviations; Address; Adult; Affect; Alzheimer' s Disease; American; Amyloid beta-42; Amyloid beta-Protein; Area; Behavior; Behavioral; Biological Assay; Biological Markers; Blood; Blood Tests; Brain; Brain imaging; Brain scan; California; Cerebrospinal Fluid; Clinical; Cognitive; Communities; Data; Data Analyses; Data Collection; Data Set; Dementia; Development; Diffusion Magnetic Resonance Imaging; Disease; Down Syndrome; Early Diagnosis; Educational process of instructing; Ensure; Etiology; Faculty; Fiber; Foundations; Future; Generations; Goals; Hippocampus (Brain); Histologic; Image; International; Knowledge; Lead; Link; Liquid substance; Longevity; MRI Scans; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Measures; Memory; Mentorship; Mission; Modernization; Monitor; Motor; Narration; Neurites; Participant; Pattern; Positron-Emission Tomography; Process; Progressive Disease; Proteins; Protocols documentation; Quality of life; Reporting; Research; Research Personnel; Resolution; Risk; Sampling; Scanning; Science; Speech; Structure; Symptoms; System; Techniques; Training; Training and Education; Treatment Effectiveness; Universities; Update; Work; analysis pipeline; base; biomarker development; career; clinical diagnosis; cognitive testing; cohort; computerized data processing; cost; data management; data sharing; data structure; density; effectiveness evaluation; gray matter; induced pluripotent stem cell; innovation; member; neuroimaging; neuroinflammation; neuropathology; next generation; novel; novel marker; outreach; prevent; symposium; tau Proteins; tau-1; white matter

Core G: Biomarker Core Project Summary/Abstract Alzheimer's is a devastating, progressive disease that affects almost 6 million Americans and this number is expected to rise to almost 14 million in the next three decades. The cost to us is immense, both on a personal and on a financial level. Our National Plan to Address Alzheimer's Disease (https://aspe.hhs.gov/report/national-plan-address-alzheimers-disease-2018-update) sets us on a path with several concrete goals and strategies to cure and prevent AD. In particular, one goal we must achieve is the early diagnosis of AD and its related disorders (AD/ADRD). If we can detect the disease early, even before symptoms have started, efforts to slow or even halt the disease may be more effective and can lead to many more years with a high quality of life. A key to this early detection is to develop biomarkers for the disease – ways in which, through testing of blood or cerebrospinal fluid (CSF – collectively known as biofluids), brain scans, or even cognitive testing – we can detect and efficiently monitor the disease and assess treatment. The goal of the UCI Biomarker Core is to help researchers here and across the globe in both collecting and analyzing data from existing measures and by developing novel measures for the purposes of identifying, quantifying, and validating factors that influence the risk of AD across the lifespan. The UCI ADRC Biomarker Core is set to provide state-of-the-art biomarker data and analyses and we will apply these to both existing data in our ADRC and to new data we are collecting. We will collect not only traditional biomarkers (blood, CSF for amyloid beta and tau, structural MRI scans, PET scans, etc.), but develop novel biomarkers as well. Our researchers have several innovative potential MRI and cognitive / behavioral biomarkers that the Core will be assisting with that have the potential to advance our overall goal of effectively determining disease etiology, measuring progression, and assessing effectiveness of treatment. In addition, we know that curing and preventing AD is a monumental challenge and that our final goal will only happen through collaborative teams and over the course of academic generations. Part of our mission in the UCI ADRC Biomarker core is therefore to share data and techniques with the research community. As big a part, however, is to share our knowledge and expertise with the next generation of clinicians and researchers, providing them with training and mentorship needed to rise to this challenge.

核心G：生物标志物核心 项目总结/摘要 阿尔茨海默氏症是一种毁灭性的，渐进性的疾病，影响近600万美国人，这个数字是 预计在未来30年内将增加到近1400万。我们付出的代价是巨大的，无论是个人的， 在财务层面上。我们的国家计划，以解决阿尔茨海默病 （https：//aspe.hhs.gov/report/national-plan-address-alzheimers-disease-2018-update）使我们走上了一条 几个具体的目标和策略来治疗和预防AD。特别是，我们必须实现的一个目标是 AD及其相关疾病（AD/ADRD）的早期诊断。如果我们能及早发现疾病， 症状已经开始，努力减缓甚至停止疾病可能会更有效，并可能导致许多 更多的岁月和高质量的生活。早期发现的关键是开发疾病的生物标志物- 通过测试血液或脑脊液（CSF -统称为生物流体）， 扫描，甚至认知测试-我们可以检测和有效地监测疾病和评估治疗。的 UCI生物标志物核心的目标是帮助这里和地球仪的研究人员收集和 分析现有措施的数据，并制定新的措施，以确定， 量化和验证影响整个生命周期AD风险的因素。 UCI ADRC生物标志物核心将提供最先进的生物标志物数据和分析，我们将 将这些应用于我们ADRC中的现有数据和我们正在收集的新数据。我们不仅会收集 传统的生物标志物（血液、淀粉样蛋白β和tau的CSF、结构MRI扫描、PET扫描等），但 开发新的生物标志物。我们的研究人员有几个创新的潜在MRI和认知/ 核心将协助的行为生物标志物，有可能推进我们的总体目标， 有效地确定疾病病因、测量进展和评估治疗有效性。在 此外，我们知道，治愈和预防AD是一个巨大的挑战，我们的最终目标只会是 通过协作团队和学术世代的过程发生。我们的使命之一是 因此，UCI ADRC生物标志物的核心是与研究界分享数据和技术。一个大 然而，部分原因是与下一代临床医生和研究人员分享我们的知识和专业知识， 为他们提供应对这一挑战所需的培训和指导。